Omeros corporation awarded $6.69 million grant from the national institute on drug abuse for its oms527 addiction program

Seattle--(business wire)--omeros corporation (nasdaq: omer) today announced that it has been awarded a grant from the national institute on drug abuse (nida), part of the national institutes of health, to develop omeros' lead orally administered compound from its proprietary phosphodiesterase 7 (pde7) program oms527 for the treatment of cocaine use disorder (cud). the grant is expected to provide $6.
OMER Ratings Summary
OMER Quant Ranking